Back to Research & Reports

Pharma M&A Boom—Understanding the Prescription for Success

Pharmaceutical M&A exceeded 2014 total deal value in Q1 2015 and deal-making opportunities continue, as covered in this Merrill webinar.

The pharma M&A boom that kicked off Q1 2015 with 35 life sciences deals totaling $166.3 billion shows no signs of slowing, reveals an expert panel on June 24, 2015, moderated by Merrill Corporation Senior Director, Richard Martin.

In the Merrill webinar Pharma M&A Boom—Understanding the Prescription for Success, our expert panel covers:

  • Forces behind increased deal activity for large and small pharma companies—and the focus of pharma investment activity.
  • How multi-billion dollar bids from Pfizer and AbbVie will impact the middle market for pharmaceuticals.
  • What investors are looking for now in the life sciences sector—and the biggest opportunity set in life sciences.

View Premium Content

Sign up once and access our entire library of premium content—white papers, webinars and reports—at any time.

All fields required*

 

I agree

This site uses cookies to offer you a better experience. For more information, view our privacy policy.